A Randomized, Double-blind, Parallel Group, Multicenter, Stratified Study Evaluating the Efficacy and Safety of Repeat Doses of GSK3772847 Compared With Placebo in Participants With Moderately Severe Asthma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Dec 2018
At a glance
- Drugs GSK-3772847 (Primary) ; Fluticasone propionate; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 13 Dec 2018 Planned End Date changed from 9 May 2019 to 23 May 2019.
- 13 Dec 2018 Planned primary completion date changed from 14 Feb 2019 to 28 Feb 2019.
- 13 Dec 2018 Status changed from recruiting to active, no longer recruiting.